(Q54643294)

2 June 2018

https://api.crossref.org/works/10.1038/NBT1010-1028

title

Tracing cancer networks with phosphoproteomics (English)

1 reference

1 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944590

1 August 2024

author name string

David B. Solit

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944590

1 August 2024

Ingo K. Mellinghoff

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944590

1 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20944590

1 August 2024

publication date

1 October 2010

1 reference

2 June 2018

full work available at URL

http://www.nature.com/articles/nbt1010-1028.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NBT1010-1028

http://www.nature.com/articles/nbt1010-1028

1 August 2024

1 reference

https://api.crossref.org/works/10.1038/NBT1010-1028

1 August 2024

1 reference

2 June 2018

volume

28

1 reference

2 June 2018

issue

10

1 reference

2 June 2018

page(s)

1028-1029

1 reference

2 June 2018

The new era in cancer research

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

The cancer biomarker problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Functional and quantitative proteomics using SILAC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1010-1028

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20944590

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20944590

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Journal of Clinical Investigation

7

118

3065

A Carracedo

2008

1 reference

https://api.crossref.org/works/10.1038/NBT1010-1028

1 August 2024

Identifiers

DOI

10.1038/NBT1010-1028

1 reference

2 June 2018

1 reference

2 June 2018